CA3053222A1 - Polypeptide variants and uses thereof - Google Patents

Polypeptide variants and uses thereof Download PDF

Info

Publication number
CA3053222A1
CA3053222A1 CA3053222A CA3053222A CA3053222A1 CA 3053222 A1 CA3053222 A1 CA 3053222A1 CA 3053222 A CA3053222 A CA 3053222A CA 3053222 A CA3053222 A CA 3053222A CA 3053222 A1 CA3053222 A1 CA 3053222A1
Authority
CA
Canada
Prior art keywords
substitution
polypeptide
antibody
group
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3053222A
Other languages
English (en)
French (fr)
Inventor
Frank Beurskens
Marije OVERDIJK
Annieck M. DIKS
Rob DE JONG
Kristin Strumane
Janine Schuurman
Paul Parren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab BV
Original Assignee
Genmab BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab BV filed Critical Genmab BV
Publication of CA3053222A1 publication Critical patent/CA3053222A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3053222A 2017-02-10 2018-02-12 Polypeptide variants and uses thereof Pending CA3053222A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201700097 2017-02-10
DKPA201700097 2017-02-10
PCT/EP2018/053464 WO2018146317A1 (en) 2017-02-10 2018-02-12 Polypeptide variants and uses thereof

Publications (1)

Publication Number Publication Date
CA3053222A1 true CA3053222A1 (en) 2018-08-16

Family

ID=61226568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3053222A Pending CA3053222A1 (en) 2017-02-10 2018-02-12 Polypeptide variants and uses thereof

Country Status (15)

Country Link
US (2) US12173076B2 (cg-RX-API-DMAC10.html)
EP (1) EP3580233A1 (cg-RX-API-DMAC10.html)
JP (2) JP7577446B2 (cg-RX-API-DMAC10.html)
KR (3) KR20240101717A (cg-RX-API-DMAC10.html)
CN (1) CN110945021B (cg-RX-API-DMAC10.html)
AU (1) AU2018218345B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019015900A2 (cg-RX-API-DMAC10.html)
CA (1) CA3053222A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991879A1 (cg-RX-API-DMAC10.html)
IL (1) IL268593B2 (cg-RX-API-DMAC10.html)
MA (1) MA47449A (cg-RX-API-DMAC10.html)
MX (1) MX2019009346A (cg-RX-API-DMAC10.html)
SG (1) SG11201906961UA (cg-RX-API-DMAC10.html)
UA (1) UA128814C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018146317A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー．ブイ． 抗体変種の組み合わせおよびその使用
US20230140384A1 (en) * 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CN113484512B (zh) * 2021-06-01 2023-06-27 中国农业科学院油料作物研究所 黄曲霉毒素风险预警智能感知卡及其应用
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
AR127743A1 (es) 2021-09-06 2024-02-28 Genmab Bv Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
WO2023206347A1 (zh) * 2022-04-29 2023-11-02 苏州瀛创生物科技有限公司 作为早老性痴呆诊断标志物的ddit4l剪切产物
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
TW202409090A (zh) 2022-05-12 2024-03-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
CN115368467B (zh) * 2022-07-19 2026-07-03 合肥天港免疫药物有限公司 双特异性抗体及其应用
IL324457A (en) 2023-05-12 2026-01-01 Genmab As Antibodies capable of binding to ox40, their variants and uses thereof
CN122249464A (zh) 2023-11-30 2026-06-19 金麦安博股份有限公司 在组合疗法中的能够结合ox40的抗体
WO2025229160A1 (en) * 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof
CN118598996B (zh) * 2024-08-08 2024-11-01 康立泰生物医药(青岛)有限公司 一种抗人白介素8抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
JP4762156B2 (ja) * 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) * 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010138725A1 (en) 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
DK2542256T3 (da) * 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
EP2920210B1 (en) 2012-11-19 2017-08-30 Baliopharm AG Recombinant bispecific antibody binding to cd20 and cd95
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質
EP3048116A1 (en) 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CA3033665A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.

Also Published As

Publication number Publication date
CN110945021B (zh) 2025-09-12
EA201991879A1 (ru) 2020-02-03
BR112019015900A2 (pt) 2020-04-07
IL268593B2 (en) 2025-05-01
US20250326854A1 (en) 2025-10-23
IL268593A (en) 2019-09-26
WO2018146317A1 (en) 2018-08-16
KR20190115057A (ko) 2019-10-10
US12173076B2 (en) 2024-12-24
AU2018218345A1 (en) 2019-08-29
AU2018218345B2 (en) 2025-04-03
KR20240101717A (ko) 2024-07-02
JP2024105709A (ja) 2024-08-06
UA128814C2 (uk) 2024-10-30
EP3580233A1 (en) 2019-12-18
JP7577446B2 (ja) 2024-11-05
MX2019009346A (es) 2019-10-02
CN110945021A (zh) 2020-03-31
IL268593B1 (en) 2025-01-01
SG11201906961UA (en) 2019-08-27
KR20250140128A (ko) 2025-09-24
US20200181277A1 (en) 2020-06-11
JP2020506208A (ja) 2020-02-27
MA47449A (fr) 2019-12-18
NZ756224A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
US20250326854A1 (en) Polypeptide variants and uses thereof
US20260132211A1 (en) Antibody variant combinations and uses thereof
US20230107363A1 (en) Polypeptide variants and uses thereof
CA3007031A1 (en) Anti-death receptor antibodies and methods of use thereof
US20210107988A1 (en) Polypeptide variants and uses thereof
US20220411529A1 (en) Antibody variant combinations and uses thereof
KR20230080437A (ko) Ror2에 결합할 수 있는 항체 및 ror2 및 cd3에 결합하는 이중특이적 항체
HK40104807A (en) Multispecific antibodies against cd40 and cd137
HK40118860A (en) Anti-death receptor antibodies and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230210

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250813

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225